[SCHEDULE 13G/A] ReShape Lifesciences, Inc. SEC Filing

Rhea-AI Filing Summary

ReShape Lifesciences received an amended Schedule 13G from L1 Capital Global Opportunities Master Fund, Ltd. reporting beneficial ownership of 7,862 shares of common stock underlying warrants, representing 0.33% of the class based on 2,385,960 shares outstanding after the offering referenced in the issuer's June 9, 2025 prospectus supplement. The filing states the shares are held by the Cayman Islands entity and clarifies that David Feldman and Joel Arber are directors of the reporting fund and may be deemed to beneficially own the securities but disclaim such ownership for other purposes. The filing affirms the position is not intended to influence control of the issuer.

Positive

• Transparent disclosure of position size and that holdings are comprised of shares underlying warrants
• Passive intent declared via Schedule 13G certification indicating no attempt to influence control

Negative

• None.

Insights

Financial Analyst

Small passive stake disclosed; immaterial to capital structure.

The filing reports a 7,862-share position via warrants equal to 0.33% of ReShape's post-offering share count. For investors, this size is below material thresholds and unlikely to affect liquidity, voting outcomes, or valuation. The use of Schedule 13G and the certification language indicate a passive, non-control intent. The disclosure of underlying warrant exposure is useful for clarity but does not change near-term financial metrics.

Corporate Governance Expert

Procedural disclosure; no control implications stated.

The filer affirms the position is held without intent to influence control and files under the passive Schedule 13G framework. Identification of directors of the reporting fund and their disclaimer of beneficial ownership for other purposes is standard governance disclosure. There is no indication of group formation or coordinated activity. From a governance perspective, this is routine compliance communication.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ReShape Lifesciences Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

76090R408

(CUSIP Number)

08/14/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 76090R408

1

Names of Reporting Persons

L1 Capital Global Opportunities Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,862.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,862.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,862.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.33 %

12

Type of Reporting Person (See Instructions)

FI

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ReShape Lifesciences Inc.
(b)	Address of issuer's principal executive offices: 18 Technology Drive, Suite 110, Irvine, CA 92618
Item 2.
(a)	Name of person filing: L1 Capital Global Opportunities Master Fund, Ltd.
(b)	Address or principal business office or, if none, residence: 161A Shedden Road, 1 Artillery Court, PO Box 10085 Grand Cayman, Cayman Islands KY1-1001
(c)	Citizenship: Cayman Islands
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 76090R408
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 7,862 The amounts in Row (5), (7) and (9) represent 7,862 shares of Common Stock underlying Warrants. The percentage set forth on Row (11) of the cover page for the reporting person is based on 2,385,960 Common Stock outstanding after the offering, based on the Issuer's Prospectus Supplement filed under Rule 424(b)(5) with the Securities and Exchange Commission on June 9, 2025. David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer's securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.
(b)	Percent of class: 0.33%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 7,862
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 7,862
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

L1 Capital Global Opportunities Master Fund, Ltd.

Signature:	/s/ David Feldman
Name/Title:	David Feldman, Director
Date:	08/14/2025

FAQ

How many ReShape Lifesciences (RSLS) shares does L1 Capital Global Opportunities Master Fund, Ltd. report owning?

The filer reports beneficial ownership of 7,862 shares of common stock underlying warrants.

What percentage of RSLS does the reported 7,862 shares represent?

The filing states this represents 0.33% of the class based on 2,385,960 shares outstanding after the referenced offering.

When was the Schedule 13G/A filed for ReShape Lifesciences (RSLS)?

The event date shown in the filing is 08/14/2025 and the signature is dated the same day.

Who signed the Schedule 13G/A for L1 Capital Global Opportunities Master Fund, Ltd.?

The filing is signed by David Feldman, Director on behalf of the reporting fund.

Are the reported holdings intended to influence control of ReShape Lifesciences?

No. The filer certifies the securities were not acquired and are not held to change or influence control of the issuer.

Are the reported shares direct holdings or underlying instruments?

The amounts represent shares of Common Stock underlying Warrants, as stated in the filing.